Miracor’s PICSO® System is used for the first time under CE mark in UK to treat an acute heart attack (STEMI) patient
A 38-year-old female is discharged from Manchester Royal Infirmary (Manchester, England) after successful PICSO treatment designed to improve myocardial perfusion following primary PCI
“In severe heart attack patients, primary PCI alone is not sufficient to eliminate the risk of recurrent cardiovascular events in up to 40% of such patients. These patients may be helped by PICSO.” - Jon H. Hoem, CEO, Miracor Medical Systems
VIENNA, Austria—Miracor Medical Systems GmbH announced today that its PICSO® System was used for the first time under CE mark in the UK to treat a patient with a large acute heart attack (STEMI). Interventional cardiologist Dr. Magdi El-Omar performed the PICSO procedure at Manchester Royal Infirmary (Manchester, England). His patient, a 38-year-old female, has been discharged from the hospital.
Click here for video animation of PICSO®.
“PICSO has the potential to become standard of care in patients presenting with acute STEMI who may benefit from this technology as a complementary procedure following PCI. By favorably redistributing blood towards ischemic myocardium, PICSO may limit infarct size and thus reduce adverse outcomes, including heart failure, which occur in up to two in five of these patients despite a successful percutaneous coronary intervention procedure,” said Dr. El-Omar.
“A successful coronary angioplasty is not adequate in up to 40 percent of STEMI patients in whom suboptimal myocardial reperfusion still persists, despite achievement of normal epicardial vessel flow. This unsatisfactory outcome is unequivocally linked to adverse outcomes in these patients, including death and heart failure,” said Jon H. Hoem, Miracor CEO. “Results like those obtained by Dr. El-Omar are critically important as we establish the clinical necessity for the PICSO procedure as a requisite complement to PCI in severe heart attack patients. Clinical use of the PICSO technology in normal care will shorten the learning curve for Miracor and our key opinion leaders, thereby improving outcomes and reduce health care costs long term. In addition to routine use of the PICSO technology, our 40-patient ‘Prepare RAMSES’ is underway and expected to further demonstrate that PICSO considerably amplifies redistribution of blood into the blood-starved myocardium of severe heart attack patients, even after a successful PCI procedure,” added Hoem.
Source: Miracor Medical Systems GmbH
Miracor’s PICSO® System is used for the first time under CE mark in UK to treat an acute heart attack (STEMI) patient
- Log in to post comments
Comments